Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BEVIMI is a brain health and wellness platform company founded in 2025 by veteran healthcare and biotechnology leaders, including former executives from Thorne HealthTech and Tempus. Headquartered in Greenwich, Connecticut, the company aims to bring pharmaceutical-style rigor to the consumer brain-health market by combining multi-pathway nutritional formulations with diagnostics, biomarkers, and AI-driven insights. Its flagship product, Uno Protect, is a daily liquid formulation designed to address neuroinflammation, support blood-brain barrier integrity, and promote cognitive longevity. BEVIMI is initiating a randomized, double-blind, placebo-controlled clinical trial in 2026 to evaluate the safety and biomarker efficacy of its formulations, establishing a new standard of clinical evidence in the nutritional supplement industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BEVIMI.